Result of AGM
LONDON--(BUSINESS WIRE)--
26 June 2025
Next 15 Group plc
('Next 15' or the 'Company')
Results of Annual General Meeting
Next 15 Group plc announces that at its Annual General Meeting held at 9:30am on 26 June 2025 at 60 Great Portland Street, London, W1W 6RT, all resolutions set out in the Notice of Annual General Meeting dated 6 May 2025, other than resolution 8 which was withdrawn, were duly passed by shareholders. Resolutions 1 to 13 were Ordinary Resolutions and Resolutions 14 to 17 were Special Resolutions. A summary of the resolutions passed and details of the proxy votes received are detailed below:
Resolutions
Votes
For1
Votes
Against
Total Votes
Cast
Votes Witheld3
No. of Shares
% of Shares voted
No. of Shares
% of Shares voted
No. of Shares
% of ISC voted2
1
To receive and adopt the Annual Report & Accounts for the year ended 31 January 2025
79,016,751
99.99%
371
0.01%
79,017,122
78.29%
298,772
2
To receive and approve the Directors' Remuneration Report for the year ended 31 January 2025
71,326,326
89.93%
7,986,123
10.07%
79,312,449
78.59%
3,445
3
To declare a final dividend of 10.6p per ordinary share
79,313,728
99.99%
371
0.01%
79,314,099
78.59%
1,795
4
To elect Mark Astaire as a Director
79,303,363
99.99%
6,088
0.01%
79,309,451
78.58%
6,443
5
To elect Mickey Kalifa as a Director
79,283,399
99.97%
27,752
0.03%
79,311,151
78.58%
4,743
6
To elect Samantha Wren as a Director
79,305,844
99.99%
4,088
0.01%
79,309,932
78.58%
5,962
7
To re-elect Penny Ladkin-Brand as a Director
76,572,297
98.52%
1,152,791
1.48%
77,725,088
77.01%
1,590,806
9
To re-elect Jonathan Peachey as a Director
79,282,994
99.97%
26,457
0.03%
79,309,451
78.58%
6,443
10
To re-elect Paul Butler as a Director
78,982,960
99.59%
326,491
0.41%
79,309,451
78.58%
6,443
11
To re-appoint Deloitte LLP as Auditor to the Company
79,171,833
99.82%
139,401
0.18%
79,311,234
78.58%
4,660
12
To authorise the Audit and Risk Committee (for and on behalf of the Board of Directors) to determine the Auditors' remuneration
79,173,104
99.82%
138,944
0.18%
79,312,048
78.59%
3,846
13
To authorise the Board to allot shares
70,538,545
88.95%
8,765,534
11.05%
79,304,079
78.58%
11,815
14
To authorise the disapplication of pre-emption rights
71,704,464
90.42%
7,599,765
9.58%
79,304,229
78.58%
11,665
15
To authorise the disapplication of pre-emption rights for the purposes of acquisitions or specified capital investment
70,085,275
88.38%
9,218,954
11.62%
79,304,229
78.58%
11,665
16
To authorise the Company to purchase its own shares
66,638,948
99.99%
3,033
0.01%
66,641,981
66.03%
12,673,913
17
That, subject to court approval, the amount standing to the credit of the Company's share premium account be cancelled
79,308,291
99.99%
5,387
0.01%
79,313,678
78.59%
2,216
Expand
1
Includes discretionary votes.
2
As at 24 June 2025, being the AGM voting record date, the Company's issued share capital ('ISC') consisted of 100,924,813 ordinary shares of 2.5p each ('Ordinary Shares'). No Ordinary Shares are held in treasury. Shareholders are entitled to one vote per share.
3
A "Vote Withheld" is not a vote in law and is not included in the calculation of votes "For" or "Against" a resolution.
Expand
Enquiries
Next 15 Group plc
Mark Sanford, General Counsel & Company Secretary
+44 (0) 7590 928794
Deutsche Numis (Nomad & Joint Broker)
+44 (0)20 7260 1000
Mark Lander
Hugo Rubinstein
Berenberg (Joint Broker)
+44 (0)20 3207 7800
Ben Wright
Mark Whitmore
MHP
Simon Evans
Eleni Menikou
Veronica Farah
+44 (0)7812 590 682
Next15@mhpgroup.com
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
36 minutes ago
- Business Wire
Verasonics Announces Enhancements to the Vantage ® NXT Research Ultrasound Platform Designed to Further Improve Capabilities in Ultrasound Research and Product Development
KIRKLAND, Wash.--(BUSINESS WIRE)-- Verasonics, Inc., the leader in research ultrasound, today announced the release of new systems and features for the Vantage NXT Research Ultrasound Platform to advance ultrasound research and product development. New enhancements include Vantage NXT 32LE and 64 System configuration models and Acquisition SDK Option features. This release will be available to all Vantage NXT customers today. 'We are excited to showcase these new enhancements with configurations and features to advance research in Biomedical, Materials Science and Industrial R&D arenas.' Enhancements to Vantage NXT in the Update include: Vantage NXT 32LE and Vantage NXT 64 system models – Available in Mid- and High-Frequency ranges, these 32- and 64-channel model configurations are ideal for customers requiring low-channel data acquisition with transmit and receive data as well as Non-Destructive Evaluation (NDE) / Non-Destructive Testing (NDT) and Materials Science research. In addition, Verasonics has released two additional Universal Transducer Adapters (UTAs) for Vantage NXT – the NXT UTA 260-MUX and NXT UTA 408-GE MUX. Acquisition SDK Option – Launched in March, the Acquisition SDK now includes programming capability for the NXT UTA 256 Direct and NXT UTA 64 LEMO, as well as the Extended Transmit Option and Vantage NXT HIFU configurations. Acquisition SDK, a C-based API, allows Vantage NXT users to program their system without MATLAB ® dependencies. The Acquisition SDK, which is comprised of a C-API, example code, and documentation, offers users similar data structures and naming conventions to those of the MATLAB Programming Model to simplify the porting of existing sequences to the Acquisition SDK environment. The Acquisition SDK is an ideal complement for users who aim to develop applications intended for commercialization or for integration of their legacy or third-party software to run on the Vantage NXT Platform. These enhancements in this update expand features for Vantage NXT users and provide more options to those considering an uptrade from the Vantage Research Ultrasound System to the Vantage NXT Research Ultrasound System. Contact sales@ regarding uptrade options. 'The Vantage NXT platform continues to expand to meet the needs of academic and commercial customers across the globe,' said Jon K. Daigle, President and Chief Executive Officer at Verasonics. 'We are excited to showcase these new enhancements with configurations and features to advance research in Biomedical, Materials Science and Industrial R&D arenas.' Visit our website for more information about Vantage NXT Research Ultrasound Systems. About Verasonics, Inc. Verasonics is a privately held company founded in 2001, with headquarters in Kirkland, Washington, USA. Verasonics, the leader in research ultrasound, is focused on providing researchers and developers with the most advanced and flexible tools enabling them to develop new algorithms and products used in biomedical ultrasound, materials science, earth sciences, and the physics of acoustics and ultrasonics. Verasonics also licenses its technology to companies for use in their commercial products. Researchers in countries across North and South America, Europe, Asia and Oceania routinely use Verasonics product solutions to advance the art and science of ultrasound through their own research efforts. Learn more by visiting the Verasonics website or following us on LinkedIn and X (Formerly Twitter).
Yahoo
an hour ago
- Yahoo
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
PARIS, June 26, 2025--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas (USA). This strategic facility is dedicated to developing novel radiopharmaceuticals and conducting preclinical research focused on targeted alpha therapies using lead-212 (212Pb), an innovative and promising approach against various types of cancer. The site hosts the R&D teams of Orano Med as well as those of its subsidiary Macrocyclics, a manufacturer of customized chelating agents. With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice (GMP) production capacity for early clinical trial supply. In addition, about 5,500 ft² of new office space has been added to accommodate the site's growing team, whose headcount has doubled over the past four years. Overall, this represents about a 50% increase in space compared to the pre-existing facility. Julien Torgue, Chief Scientific Officer of Orano Med, stated: "The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic. With an integrated platform, cutting-edge equipment and a focused scientific strategy, we are well positioned to support both our internal developments and collaborations with partners." Orano Med's R&D platform is fully integrated, combining cutting-edge equipment and a highly experienced team to advance the development of next-generation cancer therapies. The company can carry out the full range of preclinical development studies, including in vivo and Chemistry, Manufacturing and Controls (CMC) studies, onsite. Orano Med conducts both in-house research programs and collaborative developments with biotech and pharmaceutical partners. This integrated approach ensures a rapid and reliable transition from research to clinical phases. While the primary mission of the research and development center is therapeutic development, the facility also serves as production hub for lead-212 based drug candidates for early-stage clinical trials in the U.S. This expansion demonstrates Orano Med's strong commitment to innovation and leadership in the field of radioligand therapies, accelerating the development of new treatment options for patients worldwide. A celebration was held on-site with local teams and Orano Med's Executive Committee to mark this important milestone. During the event, Orano Med also unveiled the new name of the facility: Drug Development and Preclinical Unit (DDPU) – George de Hevesy Center Arnaud Lesegretain, President and Chief Executive Officer of Orano Med, added: "This expansion marks an important step in Orano Med's growth at our Plano site, which has played a key role since the inception of the company 15 years ago. It reinforces our world-class R&D capabilities in the U.S. and strengthens our ability to deliver innovative targeted alpha therapies by supporting early-stage development in a fully integrated environment." About Orano Med Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally. For more information, please visit: About Orano As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow. Orano, giving nuclear energy its full value. About Targeted Alpha Therapy Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. View source version on Contacts Mike SinclairHalsin Partnersmsinclair@
Business Wire
an hour ago
- Business Wire
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
PARIS--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas (USA). This strategic facility is dedicated to developing novel radiopharmaceuticals and conducting preclinical research focused on targeted alpha therapies using lead-212 (212 Pb), an innovative and promising approach against various types of cancer. The site hosts the R&D teams of Orano Med as well as those of its subsidiary Macrocyclics, a manufacturer of customized chelating agents. 'The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic." Share With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice (GMP) production capacity for early clinical trial supply. In addition, about 5,500 ft² of new office space has been added to accommodate the site's growing team, whose headcount has doubled over the past four years. Overall, this represents about a 50% increase in space compared to the pre-existing facility. Julien Torgue, Chief Scientific Officer of Orano Med, stated: 'The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic. With an integrated platform, cutting-edge equipment and a focused scientific strategy, we are well positioned to support both our internal developments and collaborations with partners.' Orano Med's R&D platform is fully integrated, combining cutting-edge equipment and a highly experienced team to advance the development of next-generation cancer therapies. The company can carry out the full range of preclinical development studies, including in vivo and Chemistry, Manufacturing and Controls (CMC) studies, onsite. Orano Med conducts both in-house research programs and collaborative developments with biotech and pharmaceutical partners. This integrated approach ensures a rapid and reliable transition from research to clinical phases. While the primary mission of the research and development center is therapeutic development, the facility also serves as production hub for lead-212 based drug candidates for early-stage clinical trials in the U.S. This expansion demonstrates Orano Med's strong commitment to innovation and leadership in the field of radioligand therapies, accelerating the development of new treatment options for patients worldwide. A celebration was held on-site with local teams and Orano Med's Executive Committee to mark this important milestone. During the event, Orano Med also unveiled the new name of the facility: Drug Development and Preclinical Unit (DDPU) – George de Hevesy Center Arnaud Lesegretain, President and Chief Executive Officer of Orano Med, added: 'This expansion marks an important step in Orano Med's growth at our Plano site, which has played a key role since the inception of the company 15 years ago. It reinforces our world-class R&D capabilities in the U.S. and strengthens our ability to deliver innovative targeted alpha therapies by supporting early-stage development in a fully integrated environment.' About Orano Med Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212 Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212 Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212 Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212 Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally. For more information, please visit: About Orano As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow. Orano, giving nuclear energy its full value. About Targeted Alpha Therapy Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies.
